Description
CEO Amir Reichman will review Scinai’s 2023 accomplishments and discuss 2024 plans, including bringing Scinai’s anti-IL-17 VHH antibody (‘NanoAb’) innovative psoriasis treatment into clinical trials by the end of 2024.
Comments
Rate This Webinar
Publisher
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases.